Antidepressant efficacy and side effect burden: an updated guide for clinicians

Area of Science:

• Pharmacology
• Neuroscience
• Psychiatry

Background:

• Antidepressant treatment has evolved since the 1950s with tricyclic antidepressants and monoamine oxidase inhibitors.
• The heterogeneity of major depressive disorder (MDD) is evident, with many individuals remaining symptomatic despite medication adherence.
• Research into the neurobiology of MDD has led to newer medications targeting specific neurotransmitters.

Purpose of the Study:

• To provide clinicians with updated information on managing treatment-resistant major depressive disorder.
• To review novel antidepressant medications, augmentation strategies, and nonpharmaceutical interventions.

Main Methods:

• Literature review of classic and modern antidepressant treatments for MDD.
• Inclusion of information on atypical antipsychotic augmentation, over-the-counter options, and nonpharmaceutical approaches.

Main Results:

• The review synthesizes current knowledge on a range of treatment options beyond standard antidepressants.
• It highlights the importance of personalized treatment strategies for patients with persistent symptoms.

Conclusions:

• Clinicians should consider a broad spectrum of treatments, including novel medications and non-pharmacological options, for patients with treatment-resistant MDD.
• Tailoring treatment to individual patient needs is crucial for managing persistent depressive symptoms.